BACKGROUND: Rises in the incidence of bacterial infections, such as infective endocarditis (IE), have been reported in conjunction with the opioid crisis. However, recent trends for IE and other serious infections among persons with substance use disorders (SUDs) are unknown. METHODS: Using the Premier Healthcare Database, we identified hospitalizations from 2012 through 2017 among adults with primary discharge diagnoses of bacterial infections and secondary SUD diagnoses, using International Classification of Diseases, Clinical Modification Ninth and Tenth Revision codes. We calculated annual rates of infections with SUD diagnoses and evaluated temporal trends. Blood and cardiac tissue specimens were identified from IE hospitalizations to describe the microbiology distribution and temporal trends among hospitalizations with and without SUDs. RESULTS: Among 72 481 weighted IE admissions recorded, SUD diagnoses increased from 19.9% in 2012 to 39.4% in 2017 (P < .0001). Hospitalizations with SUDs increased from 1.1 to 2.1 per 100 000 persons for IE, 1.4 to 2.4 per 100 000 persons for osteomyelitis, 0.5 to 0.9 per 100 000 persons for central nervous system abscesses, and 24.4 to 32.9 per 100 000 persons for skin and soft tissue infections. For adults aged 18-44 years, IE-SUD hospitalizations more than doubled, from 1.6 in 2012 to 3.6 in 2017 per 100 000 persons. Among all IE-SUD hospitalizations, 50.3% had a Staphylococcus aureus infection, compared with 19.4% of IE hospitalizations without SUDs. CONCLUSIONS: Rates of hospitalization for serious infections among persons with SUDs are increasing, driven primarily by younger age groups. The differences in the microbiology of IE hospitalizations suggest that SUDs are changing the epidemiology of these infections. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
BACKGROUND: Rises in the incidence of bacterial infections, such as infective endocarditis (IE), have been reported in conjunction with the opioid crisis. However, recent trends for IE and other serious infections among persons with substance use disorders (SUDs) are unknown. METHODS: Using the Premier Healthcare Database, we identified hospitalizations from 2012 through 2017 among adults with primary discharge diagnoses of bacterial infections and secondary SUD diagnoses, using International Classification of Diseases, Clinical Modification Ninth and Tenth Revision codes. We calculated annual rates of infections with SUD diagnoses and evaluated temporal trends. Blood and cardiac tissue specimens were identified from IE hospitalizations to describe the microbiology distribution and temporal trends among hospitalizations with and without SUDs. RESULTS: Among 72 481 weighted IE admissions recorded, SUD diagnoses increased from 19.9% in 2012 to 39.4% in 2017 (P < .0001). Hospitalizations with SUDs increased from 1.1 to 2.1 per 100 000 persons for IE, 1.4 to 2.4 per 100 000 persons for osteomyelitis, 0.5 to 0.9 per 100 000 persons for central nervous system abscesses, and 24.4 to 32.9 per 100 000 persons for skin and soft tissue infections. For adults aged 18-44 years, IE-SUD hospitalizations more than doubled, from 1.6 in 2012 to 3.6 in 2017 per 100 000 persons. Among all IE-SUD hospitalizations, 50.3% had a Staphylococcus aureus infection, compared with 19.4% of IE hospitalizations without SUDs. CONCLUSIONS: Rates of hospitalization for serious infections among persons with SUDs are increasing, driven primarily by younger age groups. The differences in the microbiology of IE hospitalizations suggest that SUDs are changing the epidemiology of these infections. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
Entities:
Keywords:
bacterial infection; endocarditis; injection drug use; opioid; substance use
Authors: Linda W Njoroge; Sadeer G Al-Kindi; George Augustine Koromia; Chantal A ElAmm; Guilherme H Oliveira Journal: JAMA Cardiol Date: 2018-08-01 Impact factor: 14.676
Authors: Salil V Deo; Sajjad Raza; Ankur Kalra; Vaishali S Deo; Salah E Altarabsheh; Aisha Zia; Muhammad Shahzeb Khan; Alan H Markowitz; Joseph F Sabik; Soon J Park Journal: J Am Coll Cardiol Date: 2018-04-10 Impact factor: 24.094
Authors: Andrew D Wiese; Marie R Griffin; C Michael Stein; William Schaffner; Robert A Greevy; Edward F Mitchel; Carlos G Grijalva Journal: BMJ Open Date: 2018-06-19 Impact factor: 2.692
Authors: Megan C Kelly; Samantha D Yeager; Mahmoud A Shorman; Laurence R Wright; Michael P Veve Journal: Antimicrob Agents Chemother Date: 2021-09-20 Impact factor: 5.191
Authors: Thomas D Brothers; Dan Lewer; Nicola Jones; Samantha Colledge-Frisby; Michael Farrell; Matthew Hickman; Duncan Webster; Andrew Hayward; Louisa Degenhardt Journal: PLoS Med Date: 2022-07-19 Impact factor: 11.613
Authors: Ayesha Appa; Meredith Adamo; Stephenie Le; Jennifer Davis; Lisa Winston; Sarah B Doernberg; Henry Chambers; Marlene Martin; Nancy K Hills; Phillip O Coffin; Vivek Jain Journal: Clin Infect Dis Date: 2022-01-29 Impact factor: 9.079
Authors: Mohammad Alrawashdeh; Michael Klompas; Simeon Kimmel; Marc R Larochelle; Runa H Gokhale; Raymund B Dantes; Brooke Hoots; Kelly M Hatfield; Sujan C Reddy; Anthony E Fiore; Edward J Septimus; Sameer S Kadri; Russell Poland; Kenneth Sands; Chanu Rhee Journal: Crit Care Med Date: 2021-12-01 Impact factor: 9.296
Authors: Laura R Marks; Nathanial S Nolan; Linda Jiang; Dharushana Muthulingam; Stephen Y Liang; Michael J Durkin Journal: Open Forum Infect Dis Date: 2020-09-09 Impact factor: 3.835